Meeting
2022 ASCO Annual Meeting
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.
Authors
Debbie Robbrecht
Erasmus MC Cancer Institute, Rotterdam, Netherlands
Debbie Robbrecht , Bernard Doger , Jean-Jacques Grob , Oliver Edgar Bechter , Maria J. de Miguel , Maria Vieito , Dirk Schadendorf , Giuseppe Curigliano , Ivan Borbath , Marcus O. Butler , Alejo Rodriguez-Vida , Wilson H. Miller Jr., Tun Tun Lin , Nina Masson , Clemence Pouzin , Rui Wang , Brigitte Demers , Amele Amrate , Giovanni Abbadessa , Matteo Simonelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT03192345
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2524)
DOI
10.1200/JCO.2022.40.16_suppl.2524
Abstract #
2524
Poster Bd #
180
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.
First Author: Michael A. Postow
Poster
2022 ASCO Annual Meeting
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
First Author: Dirk Schadendorf
Poster
2021 ASCO Annual Meeting
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
First Author: Thorsten Oliver Goetze
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long